A new form of acute adverse reaction to icodextrin in a peritoneal dialysis patient

Icodextrin allergy in a peritoneal dialysis patient.

Unexplained hypotension and exertional dyspnea in a night-cycled peritoneal dialysis patient--a rare form of icodextrin hypersensitivity.

In recent years, icodextrin 7.5% has been used in PD as an alternative to glucose to achieve sustained reliable ultrafiltration (UF) and clearance without adversely increasing glucose absorption. Icodextrin is generally well tolerated. The most commonly reported adverse events are cutaneous reactions. We report a rare form of hypersensitivity to icodextrin 7.5% that was accompanied by dyspnea a...

Clinical effects of icodextrin in peritoneal dialysis

Objective. This study reviews the relevant publications on the clinical effects of icodextrin in peritoneal dialysis (PD). Design. The study provides a systematic review of the literature (MEDLINE search with icodextrin as the keyword). Results. Icodextrin induces sustained transcapillary ultrafiltration during long dwell periods. It also stimulates increased removal of sodium by the peritoneal...

EXTRANEAL (icodextrin) peritoneal dialysis solution Label

WARNING: UNRECOGNIZED HYPOGLYCEMIA RESULTING FROM DRUG-DEVICE INTERACTION See full prescribing information for complete boxed warning • Use of non-specific glucose monitors has resulted in falsely elevated glucose readings due to maltose interference leading to inappropriate insulin administration or withholding of hypoglycemia treatment. Permanent neurological damage and death have been report...

Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane.

Using changes in cell counts and levels of cancer antigen 125 (CA125), fibrinogen degradation product (FDP), and interleukin-6 (IL-6) in effluent before and after the use of icodextrin-based peritoneal dialysis solution (icodextrin), we evaluated the effects of icodextrin on peritoneal membrane. The subjects were 8 anuric patients (4 men, 4 women) who had been using a 2.5% glucose-based dialysi...